
Best Practices for Using Long-acting Injectable Antipsychotics during COVID-19
Join Drs Les Citrome, Steve Stoner, and Board Certified Family Psychiatric Nurse Practitioner Tory Woodward for this on-demand online activity, as they discuss considerations for implementing LAI clinics and best practices for communicating with patients, caregivers, and clinicians regarding the use of LAIs during the global health pandemic of COVID-19.
This activity is supported by an educational grant from Alkermes.
This activity has been developed and accredited by Creative Educational Concepts, Inc. in partnership with the College of Psychiatric and Neurologic Pharmacists (CPNP).
Target Audience
Physicians, pharmacists, nurse practitioners, and nurses treating patients with LAIs in the time of COVID-19.
Learning Objectives
- Provide guidance for clinicians in setting up the ability to administer LAIs, including an overview of best practices, and expansion of scope of practice of pharmacists.
- Review best practices for patient and provider and interprofessional interactions during public health emergencies such as COVID-19.
Additional Information
Leslie Citrome, MD, MPH (Activity Chair)
Clinical Professor, Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York
Dr. Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York, and has a private practice in Pomona, New York. He also is a member of the Board of Directors of the American Society of Clinical Psychopharmacology. Dr. Citrome spent nearly two decades as a researcher in psychopharmacological treatment of severe mental disorders, including the management of treatment-refractory schizophrenia, and the management of aggressive and violent behavior.
Dr. Citrome is the Editor-in-Chief of the International Journal of Clinical Practice, and is the author or co-author of more than 400 published research reports, reviews, book chapters, and books in the biomedical literature. He has lectured extensively throughout the United States, Canada, Europe, and Asia.
Steven C. Stoner, PharmD, BCPP
Associate Dean for Student Affairs and Clinical Professor
UMKC School of Pharmacy
Division of Pharmacy Practice and Administration
Kansas City, Missouri
Dr. Stoner is Chair of Pharmacy Practice and Administration at University of Missouri-Kansas City (UMKC). In 1997, he was awarded a New Clinical Drug Evaluation Unit (NCDEU) National Institute of Mental Health (NIMH) Young Investigator Award; and in 2001, he received the College of Psychiatric and Neurologic Pharmacists (CPNP) AstraZeneca Clinical Pharmacy Practice and Administration Award. In 2006, Dr. Stoner completed the American Association of Colleges of Pharmacy (AACP) Academic Leadership Fellows Program. Additionally, he has been the recipient of both teacher- and preceptor-of-the-year awards while at UMKC.
Dr. Stoner has been a member of CPNP since 1997, has served for four years on the Recertification Committee, and has been elected to the Board of Directors as Member-at-Large. He served as the Director of an ASHP-accredited psychiatric Pharmacy Practice and Administration residency program for 10 years (1998–2008), and has served as President of the Mid-America Colleges of Clinical Pharmacy (MACCP). He also is a member of the American Society of Health-Systems Pharmacists (ASHP) and the Missouri Society of Health-Systems Pharmacists (MSHP). Dr. Stoner has authored articles that have been published in journals such as American Journal of Pharmacy Education, Clinical Therapeutics, and Journal of Pharmacy Practice.
Tory A. Woodard, PMHNP-BC
Personal Growth Counseling
Cookeville, Tennessee
Tory A. Woodard is a Board Certified Family Psychiatric Nurse Practitioner. His education includes a BS in Psychology from Tennessee State University, an MA in Clinical Psychology from Middle Tennessee University, and a MSN from Vanderbilt University. Along with the training he has received, Tory utilizes a natural, caring approach to promote well-being in the client he serves.
Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Planners
Leslie Citrome, MD, MPH–has disclosed that he is a consultant for Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, and Vanda. He receives royalties from Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics. He is also a member of the speakers’ bureau for Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, and Teva.Susan Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Steve Stoner, PharmD, BCPP–has disclosed that he is on the speakers’ bureau for Neurocrine.
Tory A. Woodard, PMHNP-BC–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty
Leslie Citrome, MD, MPH–has disclosed that he is a consultant for Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, and Vanda. He receives royalties from Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics. He is also a member of the speakers’ bureau for Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, and Teva.
Steve Stoner, PharmD, BCPP–has disclosed that he is on the speakers’ bureau for Neurocrine.
Tory A. Woodard, PMHNP-BC–has no relevant financial relationships to disclose in relation to the content of this activity.
Content Reviewers
Andrew Cutler, MD-has disclosed that he is a consultant for Alkermes, IntraCellular Therapies, Janssen, Lundbeck, Otsuka, and Sunovion; he receives grant/research support from Alkermes IntraCellular Therapies Janssen, Lundbeck, Otsuka, and Sunovion. He also is a member of the speakers’ bureau for Alkermes, IntraCellular Therapies, Janssen, Lundbeck, Otsuka, and Sunovion.
Deanna Kelly, PharmD, BCPP–has disclosed that she is consultant for Alkermes.
Amanda Simonton, ARNP–has disclosed that she is on a Medscape Education Steering Committee that is supported by grant money from Alkermes.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medicine (ACCME): CEC designates this live educational activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners (AANP): This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20084425. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Nursing (ANCC): This activity is designated for 0.50 contact hours.
Upon completion of the activity, statements of credit for physicians and nurses will be issued automatically.
Available Credit
- 0.50 AANP Contact Hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation